New warnings added to controversial antibiotic

Sanofi-Aventis has added new warnings to its antibiotic Ketek after talks with the FDA. The drug company says the warnings are intended to update doctors and patients on potential adverse events. But the warning is unlikely to quell the controversy around the drug, which has been linked to 12 cases of liver damage. Sanofi-Aventis says the rewards still outweigh any risks associated with Ketek.

- read the AFX report [1] on Ketek